Eastern Times, New Delhi: American pharma giant Pfizer becomes the first pharmaceutical agency to seek emergency use authorisation from the Drug Controller General of India (DCGI) for COVID 19 vaccine in India after clearance from Britain and Bahrain.
Pfizer is keen to test the application of the vaccine in India under the 2019 New Drugs and Clinical Trial.
DCGI was the first to receive such a request from Pfizer in a rat race to make the antidote. According to a source, Pfizer has submitted an application on December 4 to the DCGI seeking an emergency use authorization (EUA) for its COVID-19 vaccine in India.
If any antidote is allowed in the country, it will have to be okayed in the trial phase. DCGI is the only regulatory body in India to approve any antidote for local experimental application.
The experimental application of the third phase showed 95 percent effectiveness of Pfizer’s drug.
Britain on Wednesday became the first country in the world to approve the Pfizer coronavirus vaccine. The British government has said that vaccination will start in that country from this week. According to the British regulator MHRA, the vaccine, which provides 95 per cent protection against Covid-19 related diseases, is safe to roll-out.
The Bahraini government has also allowed the use of the vaccine in that country.
